Compass Pathways Announces Strategic Collaboration With Radial to Advance Patient Experience and Inform Delivery Model for COMP360

Compass Pathways plc (Nasdaq: CMPS), a biotech company focused on accelerating patient access to evidence‑based mental health innovations, has announced a new strategic collaboration with Radial Health, Inc., marking its seventh such partnership. This alliance with Radial, a rapidly expanding national network of interventional psychiatry practices, aims to explore how Compass’s investigational COMP360 synthetic psilocybin treatment could be delivered at scale if it receives FDA approval. Radial operates clinics in five U.S. states and provides virtual assessments across the country, leveraging technology and operational expertise to optimize care delivery. Together, the companies will examine how COMP360 might integrate into Radial’s care delivery model to promote a seamless patient experience upon potential future launch. Steve Levine, Chief Patient Officer at Compass Pathways, emphasized that each strategic collaboration provides unique insights into integrating COMP360 into various healthcare settings nationwide. John Capecelatro, CEO and Co‑Founder of Radial, highlighted the potential of COMP360 to transform mental health treatment paradigms and the importance of delivering meaningful, evidence‑based solutions to patients struggling with persistent conditions. #CompassPathways #RadialHealth #COMP360 #MentalHealthInnovation #SlimScan #GrowthStocks #CANSLIM